These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 12478161)

  • 1. Bisphosphonate therapy for hormone refractory prostate cancer with bone metastasis.
    Asahi H; Mizokami A; Maeda Y; Komatsu K; Koshida K; Namiki M
    J Urol; 2003 Jan; 169(1):281-2. PubMed ID: 12478161
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of zoledronic acid on metastatic hormone-refractory prostate cancer resistant to taxane, estramustine, carboplatin, and dexamethasone.
    Kikuno N; Urakami S; Nakamura S; Shiina H; Igawa M
    Int J Urol; 2007 Jan; 14(1):82-4. PubMed ID: 17199867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance to gonadotropin-releasing hormone agonist in a patient with metastatic prostate cancer.
    Krongrad A; Brady J; Rodriguez RJ
    South Med J; 1997 Apr; 90(4):460-1. PubMed ID: 9114847
    [No Abstract]   [Full Text] [Related]  

  • 4. Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
    Efstathiou E; Bozas G; Kostakopoulos A; Kastritis E; Deliveliotis C; Antoniou N; Skarlos D; Papadimitriou C; Dimopoulos MA; Bamias A
    Urology; 2005 Jan; 65(1):126-30. PubMed ID: 15667877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Penile metastasis of prostatic adenocarcinoma.
    Senkul T; Karademir K; Silit E; Işeri C; Erden D; Baloğlu H
    Int J Urol; 2002 Oct; 9(10):597-8. PubMed ID: 12445240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of response to carboplatin in patients with hormone-refractory prostate cancer: a critical analysis of drug activity.
    Miglietta L; Cannobbio L; Boccardo F
    Anticancer Res; 1995; 15(6B):2825-8. PubMed ID: 8669872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term response to combination therapy with estramustine and somatostatin analogue in a patient with androgen ablation-refractory prostate cancer.
    Cerulli C; Sciarra A; Salvatori G; Di Silverio F
    Urology; 2004 Dec; 64(6):1231.e1-3. PubMed ID: 15596212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal toxicity following zoledronic acid reversed with ibandronate in a prostate cancer patient with bone metastases.
    Joensuu TK
    Urol Int; 2008; 80(4):448-50. PubMed ID: 18587260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significance of baseline bone markers on disease progression and survival in hormone-sensitive prostate cancer with bone metastasis.
    Nozawa M; Hara I; Matsuyama H; Iki M; Nagao K; Nishioka T; Komura T; Esa A; Uejima S; Imanishi M; Uekado Y; Ogawa T; Kajikawa H; Uemura H
    World J Urol; 2015 Sep; 33(9):1263-8. PubMed ID: 25354720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A transient increase in serum procollagen 1 carboxyterminal peptide following effective treatment in prostate cancer patients with bone metastases.
    Nakashima J; Sumitomo M; Miyajima A; Jitsukawa S; Murai M
    Urol Int; 1997; 58(4):236-8. PubMed ID: 9253125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A case of hormone/docetaxel-refractory prostate cancer in which PSA level decreased after docetaxel+zoledronic acid treatment].
    Okajima K; Yamashita Y; Onuki T; Fujinami K; Senga Y; Goto A; Jinza S; Asakura T
    Gan To Kagaku Ryoho; 2008 Jul; 35(7):1247-9. PubMed ID: 18633274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Diferelin treatment of primary local and generalized cancer of the prostate].
    Kolesnikov GP; Rusakov IG; Shaplygin LV; Voznesenskiĭ SA; Bystrov AA
    Urologiia; 2001; (6):17-9. PubMed ID: 11785073
    [No Abstract]   [Full Text] [Related]  

  • 13. Prospective study of estramustine phosphate for hormone refractory prostate cancer patients following androgen deprivation therapy.
    Hirano D; Minei S; Kishimoto Y; Yamaguchi K; Hachiya T; Yoshida T; Yoshikawa T; Endoh M; Yamanaka Y; Yamamoto T; Satoh Y; Ishida H; Okada K; Takimoto Y
    Urol Int; 2005; 75(1):43-9. PubMed ID: 16037707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Antiandrogen withdrawal syndrome in hormone refractory metastatic prostate cancer].
    Coutant G; Algayres JP; Dordain ML; Selle F; Le Berruyer PY; Bili H; Daly JP
    Rev Med Interne; 1997; 18(9):732-4. PubMed ID: 9365728
    [No Abstract]   [Full Text] [Related]  

  • 15. Case records of the Massachusetts General Hospital. Case 16-2011. A 67-year-old man with recurrent prostate cancer.
    Smith MR; Zietman AL; Finkelstein JS; Wu CL
    N Engl J Med; 2011 May; 364(21):2044-51. PubMed ID: 21612474
    [No Abstract]   [Full Text] [Related]  

  • 16. A case of metastatic cancer with markedly elevated PSA level that was not detected by repeat prostate biopsy.
    Iwamura H; Hatakeyama S; Tanaka Y; Tanaka T; Tokui N; Yamamoto H; Imai A; Yoneyama T; Hashimoto Y; Koie T; Yoshikawa K; Ohyama C
    BMC Res Notes; 2014 Jan; 7():64. PubMed ID: 24476098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is time to first skeletal-related event the best primary end point in the assessment of bisphosphonate efficacy in patients with castration-sensitive prostate cancer?
    Valcamonico F; Petrelli F; Ferrari L; Ferrari V; Grisanti S; Barni S; Berruti A
    J Clin Oncol; 2014 Nov; 32(32):3684-5. PubMed ID: 25225432
    [No Abstract]   [Full Text] [Related]  

  • 18. Dramatic PSA Increase With Tumor Shrinkage After Initiating Degarelix in Advanced Prostate Cancer.
    Ammannagari N; Javvaji C; Danchaivijitr P; George S
    Clin Genitourin Cancer; 2016 Feb; 14(1):e123-5. PubMed ID: 26508365
    [No Abstract]   [Full Text] [Related]  

  • 19. Combination therapy using LHRH and somatostatin analogues plus dexamethasone in androgen ablation refractory prostate cancer patients with bone involvement: a bench to bedside approach.
    Koutsilieris M; Bogdanos J; Milathianakis C; Dimopoulos P; Dimopoulos T; Karamanolakis D; Halapas A; Tenta R; Katopodis H; Papageorgiou E; Pitulis N; Pissimissis N; Lembessis P; Sourla A
    Expert Opin Investig Drugs; 2006 Jul; 15(7):795-804. PubMed ID: 16787142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate.
    Mackler NJ; Dunn RL; Hellerstedt B; Cooney KA; Fardig J; Olson K; Pienta KJ; Smith DC
    Cancer; 2006 Jun; 106(12):2617-23. PubMed ID: 16691618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.